BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17619162)

  • 1. Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10 ng/ml.
    Yamamoto S; Maruyama T; Kondoh N; Nojima M; Takiuchi H; Hirota S; Shima H
    Int Urol Nephrol; 2008; 40(1):85-9. PubMed ID: 17619162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Can indexes based on PSA determine which patients should undergo repeated ultrasound-guided transrectal prostatic biopsy? Study on 546 patients who underwent repeated biopsy].
    Rodríguez-Patrón Rodríguez R; Mayayo Dehesa T; González Galán A; Zuccarino AL; García González R; Cuesta Roca C
    Arch Esp Urol; 2002 Dec; 55(10):225-34. PubMed ID: 12611220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma.
    Thakur V; Singh PP; Talwar M; Mukherjee U
    Dis Markers; 2003-2004; 19(6):287-92. PubMed ID: 15258330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.
    Castro HAS; Iared W; Santos JEM; Solha RS; Shigueoka DC; Ajzen SA
    Int Braz J Urol; 2018; 44(4):709-716. PubMed ID: 29697929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
    Chakraborty L; Ahmed AN; Paul BK; Haque A; Ara A; Nabi S; Nessa M
    Mymensingh Med J; 2012 Jan; 21(1):98-102. PubMed ID: 22314462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL.
    Djavan B; Zlotta A; Kratzik C; Remzi M; Seitz C; Schulman CC; Marberger M
    Urology; 1999 Sep; 54(3):517-22. PubMed ID: 10475364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of free-to-total prostate specific antigen (F/T PSA), prostate specific antigen density (PSAD) and (F/T)/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone.
    Milkovic B; Dzamic Z; Pejcic T; Kajmakovic B; Nikolic D; Cirovic D; Knezevic T; Dzamic D; Hadzi-Djokic J
    Ann Ital Chir; 2014; 85(5):448-53. PubMed ID: 25599711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.
    Erol B; Gulpinar MT; Bozdogan G; Ozkanli S; Onem K; Mungan G; Bektas S; Tokgoz H; Akduman B; Mungan A
    Kaohsiung J Med Sci; 2014 Nov; 30(11):545-50. PubMed ID: 25458043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies?
    Prestigiacomo AF; Stamey TA
    J Urol; 1997 Jan; 157(1):189-94. PubMed ID: 8976248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PSA-related variables in improving positive ratio of biopsy of prostate cancer within serum PSA gray zone.
    Liu B; Pan TJ
    Urologia; 2014; 81(3):173-6. PubMed ID: 24557815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist.
    Hofer C; Sauerstein P; Wolter C; Scholz M; Hartung R; Breul J
    Urol Int; 2000; 64(1):18-23. PubMed ID: 10782027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population.
    Mungan AG; Erol B; Akduman B; Bozdogan G; Kiran S; Yesilli C; Mungan NA
    Clin Chem Lab Med; 2007; 45(7):912-6. PubMed ID: 17617037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
    Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
    Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimum PSA reflex-range.
    Benecchi L
    Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of prostate-specific antigen velocity in screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Kubota Y; Fukabori Y; Kurokawa K; Suzuki K; Yamanaka H
    Int J Urol; 2002 Jun; 9(6):316-21. PubMed ID: 12110095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.